Circulating Tumor Cells (CTC) - Set to Become a Regular Screening Test for Cancers

Just as common as colonoscopies and mammograms, Circulating Tumor Cells (CTC) Screening may become a regular affair for many types of cancers.

HYDERABAD, TELANGANA, INDIA, September 8, 2015 /EINPresswire.com/ -- Since cancer² is a disease of genetic mutations, the future treatments will be based on assessing how the mutation leads to cancer. Cells within a single cancer tumor may possess different mutations, and hence several targeted therapies are imperative for treating even a single type of cancer. The challenge is to develop techniques for preventing cancer and identifying cancer at its earliest stages (when cancer is more treatable). Since the average life expectancy of the world’s population is increasing, the chances of developing cancer also increase. CTC Screening is slated to be an effective mechanism for identifying cancer at its earliest stages and thereby reducing cancer deaths.

RI Technologies' market research report on Circulating Tumor Cells (CTC)¹ Technologies gives a market insight into technologies and services used for cancer detection. The market is analyzed by Cancer type into Prostate, Breast and Other; and by Function into Prognostics, Diagnostics and Therapy Management. The report serves as a guide to CTC markets, covering more than 150 companies that are engaged in CTC studies/screening, products and services. Major Contract Research Organizations, Research Institutes and Universities serving the CTC market are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents related to CTC Technologies is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, and Asia-Pacific.

The biggest technical challenge is CTC detection despite the continued development of many new technologies. The key need is for a technology that will detect the real metastasis-initiating CTC which in turn will trigger distant metastases. This may be a combination of complementary technologies or even several technologies optimized for specific tumor types. CTC enrichment depends on the different properties of CTCs that distinguish them from the surrounding normal hematopoietic cells; physical properties; and biological properties. Most of the current technologies are still based on epithelial cell adhesion molecule (EpCAM) expression. New emerging technologies may try to capture EpCAM-negative CTCs.

Global CTC Technologies market is predicted to cross US$ 12 billion by the year 2020. The worldwide cancer incidence rate is growing alarmingly. As per statistics, the number of global cancer deaths is projected to increase about 45-50% (about 8 million deaths) from 2007 to 2030 (about 12 million deaths). This is due to increasing and aging populations worldwide. Cancer is the second largest cause of death in most developed countries after cardiovascular disease, and developing countries too are now showing the same pattern. Unless tobacco controls are strictly followed, lung cancer will continue to kill more people than any other cancer. Prostate, breast and colon cancers are more common in developed countries, while liver, cervical and stomach cancers are more common in developing countries.


To order this market research report on CTC Technologies, please contact us at contactus@researchimpact.com. You may also explore customized research services on CTC Technologies with RI Technologies.


About RI Technologies

RI Technologies, www.researchimpact³.com, is a premier market research provider. The company believes in pure research that will trigger action for immediate customer needs rather than plain reporting of data. The reports provide strategic information tools that help to probe into and support critical business decisions. RI Technologies believes in broadening the value of market research obtained through several dedicated streams of information. Investment banks, companies, management consultants, trade associations, corporate executives, business analysts, libraries, universities, and business schools stand to benefit from RI Technologies' unique market research reports.


contactus@researchimpact.com

www.researchimpact.com

Anasuya Vemuri
RI Technologies
+91 9676994272
email us here

¹ http://www.researchimpact.com/global-market-research-reports/report.php?link=circulating-tumor-cells-technologies
² http://www.researchimpact.com/global-market-research-reports/report.php?link=circulating-tumor-cells-technologies
³ http://www.researchimpact.com